CAH Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 0.92% compared to Cardinal Health's net margin of 14.45%. Cardinal Health's return on equity of -- beat Boston Scientific's return on equity of 9.57%.

Cardinal Health has a consensus price target of $154.74, signalling upside risk potential of 0.82%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 10.8%. Given that Boston Scientific has higher upside potential than Cardinal Health, analysts believe Boston Scientific is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.32%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Cardinal Health's net income of $506M is lower than Boston Scientific's net income of $674M. Notably, Cardinal Health's price-to-earnings ratio is 23.94x while Boston Scientific's PE ratio is 76.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 8.89x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.6%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 155.22%.

Cardinal Health has a consensus price target of $154.74, signalling upside risk potential of 0.82%. On the other hand Cencora has an analysts' consensus of $305.82 which suggests that it could grow by 0.41%. Given that Cardinal Health has higher upside potential than Cencora, analysts believe Cardinal Health is more attractive than Cencora.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.32%. Cencora offers a yield of 0.7% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $81.5B. Cardinal Health's net income of $506M is higher than Cencora's net income of $488.6M. Notably, Cardinal Health's price-to-earnings ratio is 23.94x while Cencora's PE ratio is 43.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.20x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 0.92% compared to Cardinal Health's net margin of -45.89%. Cardinal Health's return on equity of -- beat Masimo's return on equity of -39.91%.

Cardinal Health has a consensus price target of $154.74, signalling upside risk potential of 0.82%. On the other hand Masimo has an analysts' consensus of $183.32 which suggests that it could grow by 22.13%. Given that Masimo has higher upside potential than Cardinal Health, analysts believe Masimo is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.32%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Masimo quarterly revenues of $372M. Cardinal Health's net income of $506M is higher than Masimo's net income of -$170.7M. Notably, Cardinal Health's price-to-earnings ratio is 23.94x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 4.13x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 0.92%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $154.74, signalling upside risk potential of 0.82%. On the other hand McKesson has an analysts' consensus of $709.65 which suggests that it could fall by -1.76%. Given that Cardinal Health has higher upside potential than McKesson, analysts believe Cardinal Health is more attractive than McKesson.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.32%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $95.3B. Cardinal Health's net income of $506M is lower than McKesson's net income of $879M. Notably, Cardinal Health's price-to-earnings ratio is 23.94x while McKesson's PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.27x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.